City State Bank cut its holdings in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 9.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,911 shares of the company’s stock after selling 386 shares during the quarter. Eli Lilly and comprises 0.9% of City State Bank’s investment portfolio, making the stock its 26th largest holding. City State Bank’s holdings in Eli Lilly and were worth $1,430,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of LLY. Insight Inv LLC acquired a new position in shares of Eli Lilly and in the second quarter valued at $26,000. New Millennium Group LLC bought a new stake in Eli Lilly and in the second quarter valued at $34,000. Moisand Fitzgerald Tamayo LLC grew its position in Eli Lilly and by 292.6% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 106 shares of the company’s stock valued at $34,000 after acquiring an additional 79 shares during the period. TimeScale Financial Inc. grew its position in Eli Lilly and by 87.9% in the third quarter. TimeScale Financial Inc. now owns 109 shares of the company’s stock valued at $35,000 after acquiring an additional 51 shares during the period. Finally, Bellwether Advisors LLC bought a new stake in Eli Lilly and in the third quarter valued at $47,000. 82.13% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Trading Down 0.1 %
NYSE:LLY traded down $0.35 during mid-day trading on Friday, hitting $329.18. The company had a trading volume of 8,679,808 shares, compared to its average volume of 3,187,617. The firm has a market cap of $312.82 billion, a P/E ratio of 47.71, a P/E/G ratio of 1.88 and a beta of 0.36. The company has a debt-to-equity ratio of 1.37, a quick ratio of 0.80 and a current ratio of 1.05. The business’s fifty day moving average is $335.87 and its two-hundred day moving average is $341.41. Eli Lilly and Company has a fifty-two week low of $276.83 and a fifty-two week high of $384.44.
Wall Street Analyst Weigh In
A number of analysts have weighed in on LLY shares. Guggenheim upped their price target on Eli Lilly and from $399.00 to $401.00 and gave the company a “buy” rating in a research report on Wednesday, December 7th. Cowen increased their target price on Eli Lilly and from $390.00 to $430.00 in a report on Monday, December 5th. Citigroup decreased their target price on Eli Lilly and from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Friday, March 3rd. Wells Fargo & Company upgraded Eli Lilly and from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $360.00 to $375.00 in a report on Monday, March 13th. Finally, Cowen increased their target price on Eli Lilly and from $390.00 to $430.00 and gave the stock an “outperform” rating in a report on Monday, December 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and presently has a consensus rating of “Moderate Buy” and a consensus price target of $382.05.
Insider Transactions at Eli Lilly and
In related news, EVP Anne E. White sold 2,500 shares of the stock in a transaction dated Monday, February 13th. The stock was sold at an average price of $346.47, for a total transaction of $866,175.00. Following the completion of the transaction, the executive vice president now directly owns 57,926 shares in the company, valued at $20,069,621.22. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.12% of the stock is currently owned by insiders.
About Eli Lilly and
Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.